Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK welcomes external scientists to diseases of the developing world research campus
GSK will provide support, expertise and facilities as part of our open innovation strategy to spur global collaboration in research
-
GSK statement on University of East Anglia study examining health impacts of anticholinergic medicines for over 65s
University of East Anglia published in JAGS, long term health impacts of anticholinergic medicines, group of drugs taken by older people.
-
GSK statement on agreements with State Attorneys General on former Cidra manufacturing facility
GSK agreed to pay $40.75 million as part of an agreement related to events during early 2000s at former manufacturing facility in Cidra
-
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China
GSK entered into agreement to acquire the remaining 51% equity interest of Neptunus in JV company for a total cash consideration of $39m
-
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
GSK & VRX announced that the FDA has approved Potiga Tablets, a potassium channel opener, as treatment of partial-onset seizures in 18yo+.
-
Millions of children in the world’s poorest countries could receive vaccination against rotavirus diarrhoeal disease under new offer made by GSK to the GAVI Alliance
GSK announced it's made a new offer to supply Rotarix, to the GAVI Alliance at $2.50 per dose, a small fraction of developed world prices.
-
GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas
PALETTE study presented at ASCO demonstrated improvement in the time to occurrence of tumour progression in patients on pazopanib vs placebo
-
GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD
GSK and THRX announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with COPD.
-
GSK forms partnership with three leading NGOs to address shortage of frontline healthcare workers in Least Developed Countries LDCs
- Agreements signed with AMREF, CARE International UK and Save the Children as part of commitment to reinvest 20% of profits in LDCs
-
GlaxoSmithKline and Human Genome Sciences receive positive opinion in Europe from the CHMP for Benlysta® belimumab
GSK & HGS announced that EMA's CHMP issued a positive opinion, recommending marketing authorisation for Benlysta, a lupus therapy.
-
Young peoples health charity steps forward to claim top accolade and 35,000
Step Forward, has beaten more than 400 organisations from around the UK to be crowned the overall winner of this year's GSK IMPACT Awards
-
pharmaceutical industry and university create manchester collaborative centre for inflammation research
GSK, UofM & AZN announce creation of MCCIR, unique collaboration to establish a world-leading translational centre for inflammatory diseases
-
GSK Q1 performance demonstrates continued progress with delivery of underlying sales growth, cash generation and pipeline visibility
Reported sales -10%; underlying sales* +4% EPS before major restructuring* 32.2p (+9%); dividend 16p (+7%)
-
Regulatory update – GSK and Valeant respond to FDA on ezogabine
GSK & VRX submitted on 15/04/11 the response to the FDA Complete Response letter received on 30 November 2010 for the NDA for ezogabine.
-
GSK welcomes key agreement to support global preparedness against pandemic influenza
GSK welcomes agreement reached at OEWG coordinated by WHO on a Framework to support global preparedness for a future influenza pandemic.
-
GSK European regulatory update on Pandemrix™
EMA's CHMP recommends changes to Pandemrix, including prescribing advice based on increased risk of narcolepsy in children or adolescents
-
Regulatory Update - Tyverb® lapatinib
GSK submitted a MAA to EMA for lapatinib in with paclitaxel for the treatment of metastatic breast cancer with over-express HER2 (ErbB2).
-
GlaxoSmithKline announces non-core OTC products to be divested
GSK to divest non-core OTC brands as it focuses Consumer Healthcare business around fast-growing priority brands and the emerging markets.
-
Unique research alliance expands collaboration opportunities at state-of-the-art medical imaging centre
UK research community to have access to world-class medical imaging facilities in London with the signing of an agreement between MRC & GSK
-
GlaxoSmithKline and XenoPort receive FDA approval for Horizant™
GSK & XNPT announced that the FDA has approved Horizant for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults.
